Assistant Professor, Department of Radiation Oncology
Adrenal Tumor, Leukemia, Penile Cancer, Thymoma, Kidney Cancer, Myeloma, Testicular Cancer, Urethral Cancer, Bladder Cancer, Lymphoma, Prostate Cancer, Ureteral Cancer
My primary role is as a member of the genitourinary cancer program treating adrenal tumors, kidney cancer, penile cancer, prostate cancer, bladder cancer, ureteral cancer, urethral cancer, and testicular cancer.
I have had extensive training in several specialized radiation techniques:
I earned doctorate degrees in both medicine and pharmacology research at the Medical University of South Carolina enrolled in the Medical Scientist Training Program. After graduation I joined Fox Chase Cancer Center for my medical residency training in the Department of Radiation Oncology. Upon completing residency I was recruited to become a member of the department faculty treating genitourinary cancers and hematologic cancers. As part of that role, I also conduct research and design clinical trials to both improve upon our current treatments and to develop new technologies in the fight against cancer.
While knowledge and expertise are important, I believe that compassion and personalized care are also essential to being an effective physician. I strive to establish trust and understanding with my patients in order to best help them complete complex and intense cancer therapies in order to achieve the best possible outcomes. This is an exciting time to be at Fox Chase Cancer Center. The faculty and staff at Fox Chase work as a team with the common goal of providing world class cancer treatment. Not only do I have access to state of the art technologies and cutting-edge treatments, but I also have the opportunity to develop new treatments that will improve the way we treat cancer in the future.
My research has focused on improving the safety and efficacy of delivering SBRT. I will also focus on developing new ways to deliver radiation treatments to cancers that are otherwise untreatable with conventional therapies. These methods will use exciting new drug and radiation combinations to enhance the effects and targeting of radiation on tumor cells.
Paly J.J., Egleston B.L., Wong J.K., Burbure N., Sobczak M.L., Hayes S.B., Chen D.Y.T., Horwitz E.M., Hallman M.A., Patient-reported quality of life after sbrt, ldr, and hdr brachytherapy for prostate cancer: A comparison of outcomes. Am J Clin Oncol. 44(4): 131-136, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33577175.
Wong J.K., Shaikh T., DeMora L., Zhang E., Borghaei H., Hayes S.B., Kumar S., Meyer J.E., Hallman M.A., Predictors of distant recurrence following stereotactic body radiation therapy for stage I non-small cell lung cancer. Am J Clin Oncol. 43(4): 243-248, 2020.PMC7103551. https://www.ncbi.nlm.nih.gov/pubmed/31913907.
Shaikh T, Handorf EA, Murphy C, Kutikov A, Uzzo RG, Hallman MA, Horwitz EM, Smaldone MC. Contemporary Trends in the Utilization of Radiotherapy in Patients with Renal Cell Carcinoma. Urology, 2015 Sep; in press (PMID: 2638611)
Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted" Zaorsky N, Hallman MA, Smaldone MC.
Annals of Translational Medicine, 2015 Oct; 3(18):274.
Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Knoepp SM, Chahal MS, Xie Y, Zhang Z, Brauner DJ, Hallman MA, Robinson SA, Han S, Imai M, Tomlinson S, Meier KE. Mol Pharmacol, 2008 Sep;74(3):574-84.
Regulation of dedifferentiation and redifferentiation in renal proximal tubular cells by the epidermal growth factor receptor. Hallman MA, Zhuang S, Schnellmann RG. J Pharmacol Exp Ther, 2008 May;325(2):520-8.
RasGRP1 confers the phorbol ester-sensitive phenotype to EL4 lymphoma cells. Han S, Knoepp SM, Hallman MA, Meier KE, Mol Pharmacol. 2007 Jan;71(1):314-22.
Effect of antioxidants on para-aminophenol-induced toxicity in LLC-PK1 cells. Hallman MA, Tcaho R, Tarloff JB. Toxicology, 2000 Dec;156(1):37-45.
Patient comments